SLC5A2 and type 2 diabetes mellitus: The knowledge of SGLT-2 inhibitors’ effectiveness results, nowadays, in the increasing use of these pharmacological agents as monotherapy or associated with other antidiabetic drugs both in patients with T2D and with HF (Table 2).